Owlstone Medical Announces Successful Study Using Breath Biopsy to Measure Liver Function

Owlstone Medical recently announced the success of its patient study demonstrating its Breath Biopsy®, using limonene as a biomarker in measuring liver function. The study demonstrated how exhaled limonene, a…

Continue Reading Owlstone Medical Announces Successful Study Using Breath Biopsy to Measure Liver Function
The TARGET-NASH Study Finds Prior Opioid Use Prevalent in NAFLD Patients
source: pixabay.com

The TARGET-NASH Study Finds Prior Opioid Use Prevalent in NAFLD Patients

Target RWE, an innovative health evidence solutions company based in Durham, North Carolina recently announced its current data from the study of nonalcoholic steatohepatitis (NASH) via PRNewswire. The study, entitled…

Continue Reading The TARGET-NASH Study Finds Prior Opioid Use Prevalent in NAFLD Patients
More Research Needed to Help Postmenopausal Females at Risk for Nonalcoholic Fatty Liver Disease
source: pixabay.com

More Research Needed to Help Postmenopausal Females at Risk for Nonalcoholic Fatty Liver Disease

by Natalie Homan from In The Cloud Copy A review article published in Endocrinology in August of this year highlights the fact that a female's risk of developing nonalcoholic fatty…

Continue Reading More Research Needed to Help Postmenopausal Females at Risk for Nonalcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease: Study of Children Receiving Standard of Care Lifestyle Advice

by Danielle Bradshaw from In The Cloud Copy It’s possible for fat to end up stored inside of the liver due to either obesity, diabetes, certain medications, or high cholesterol.…

Continue Reading Non-alcoholic Fatty Liver Disease: Study of Children Receiving Standard of Care Lifestyle Advice
Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment
Source: Pixabay

Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment

Alnylam Pharmaceuticals has submitted their clinical trial authorization (CTA) application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for their RNAi therapy, ALN-HSD, a treatment for nonalcoholic steatohepatitis (NASH).…

Continue Reading Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment
Data Supports Tesamorelin as Effective for HIV-Associated NASH
Arcaion / Pixabay

Data Supports Tesamorelin as Effective for HIV-Associated NASH

  Biopharmaceutical company Theratechnologies Inc. recently announced that its therapy candidate tesamorelin is effective in the treatment of HIV-associated nonalcoholic steatohepatitis (NASH). According to new data, published in JCI Insight, tesamorelin…

Continue Reading Data Supports Tesamorelin as Effective for HIV-Associated NASH
MRFF Funding Promotes Treatment Development for Patients with Rare Diseases
https://pixabay.com/en/money-piggy-bank-coins-finance-2180338/

MRFF Funding Promotes Treatment Development for Patients with Rare Diseases

  When it comes to researching and finding treatments for rare diseases, funding plays a crucial role. Recently, the Medical Research Future Fund (MRFF) Stem Cell Therapies Mission presented Monash…

Continue Reading MRFF Funding Promotes Treatment Development for Patients with Rare Diseases
NAFLD and NASH Predicted to Be a Growing Health Emergency
https://pixabay.com/en/doctor-hospital-bed-delivery-labor-840127/

NAFLD and NASH Predicted to Be a Growing Health Emergency

  In a Business Wire press release, the Canadian NASH Network (CanNASH) shared the results of a recent study predicting a severe increase in cases of nonalcoholic fatty liver disease…

Continue Reading NAFLD and NASH Predicted to Be a Growing Health Emergency
Podcast Series Released to Increase Awareness and Education for Nonalcoholic Steatohepatitis
source: pixabay.com

Podcast Series Released to Increase Awareness and Education for Nonalcoholic Steatohepatitis

International Nonalcoholic Steatohepatitis (NASH) Day takes place on June 12th every year. This year, a 4 part podcast series was released by NASHNET as part of the continued effort to spread…

Continue Reading Podcast Series Released to Increase Awareness and Education for Nonalcoholic Steatohepatitis
A New Phase 2 Trial Begins for Experimental Nonalcoholic Steatohepatitis Treatment
source: pixabay.com

A New Phase 2 Trial Begins for Experimental Nonalcoholic Steatohepatitis Treatment

According to a story from globenewswire.com, the biotechnology company CytoDyn Inc. has recently announced the initiation of a phase 2 clinical trial. This clinical trial will be testing the company's…

Continue Reading A New Phase 2 Trial Begins for Experimental Nonalcoholic Steatohepatitis Treatment
International Nonalcoholic Steatohepatitis (NASH) Day Sparks New Collaboration for Research
source: pixabay.com

International Nonalcoholic Steatohepatitis (NASH) Day Sparks New Collaboration for Research

International NASH Day, or IND, began in 2018 to raise awareness of nonalcoholic steatohepatitis (NASH). This is the most advanced form of fatty liver disease. It is a progressive condition…

Continue Reading International Nonalcoholic Steatohepatitis (NASH) Day Sparks New Collaboration for Research
Study: EDP-305 for the Treatment of Primary Biliary Cholangitis
source: pixabay.com

Study: EDP-305 for the Treatment of Primary Biliary Cholangitis

Enanta Pharmaceuticals has recently released the results from the second phase of its INTREPID trial, which studied EDP-305 as a treatment for primary biliary cholangitis (PBC). The results were positive,…

Continue Reading Study: EDP-305 for the Treatment of Primary Biliary Cholangitis
Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial
source: pixabay.com

Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial

According to a story from Biotech-365, the biopharmaceutical company Inventiva has been forced to change its plans to announce the latest updates for its phase IIb clinical trial. This clinical…

Continue Reading Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial
Planning for Phase 3 for Study of Treatment for NASH Has Begun
Source: Pixabay.com

Planning for Phase 3 for Study of Treatment for NASH Has Begun

  Galectin Therapeutics has recently started to plan the third phase of its clinical trial of belapectin, which treats nonalcoholic steatohepatitis (NASH). They are making refinements based on a conversation…

Continue Reading Planning for Phase 3 for Study of Treatment for NASH Has Begun
Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
luvqs / Pixabay

Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

  The FDA has recently approved of Viking Therapeutics' Investigational New Drug (IND) application, which allows patients to enroll in their clinical trials. In order to qualify for these trials,…

Continue Reading Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
Close Menu